CLDI

Calidi Biotherapeutics, Inc. (CLDI) Management Analysis (2026)

Invetso Score: 5/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Leadership

Score: 5.4 (Moderate)

Management has maintained strategic continuity, but negative ROE suggests leadership has not yet translated decisions into durable shareholder value versus peers.

The balance-sheet profile remains conservative, and that restraint supports flexibility, though it has not offset weak profitability relative to better-executing peers.

Limited disclosed long-term share-count data reduces visibility, but the absence of clear dilution signals suggests no obvious capital-structure missteps versus peers.

Execution

Score:

Negative return on equity indicates operating decisions have not consistently produced acceptable returns, lagging peers with stronger conversion of capital into earnings.

Low net debt to EBITDA shows execution has avoided balance-sheet stress, but weak equity returns imply operating discipline has not been sufficient to create value.

The combination of modest leverage and poor profitability points to uneven execution quality, with risk control better than earnings delivery versus peers.

Capital Allocation

Score:

Management has kept leverage moderate, and that conservative funding choice preserves optionality, but it has not yet driven superior returns versus peers.

The low net debt burden suggests capital allocation has prioritized balance-sheet safety over aggressive expansion, limiting downside but also limiting value creation.

Negative ROE implies reinvested capital has not generated attractive compounding, leaving allocation discipline below stronger peer operators.

Incentives

Score:

Publicly available metrics do not show clear incentive alignment, and the weak profitability outcome suggests pay structures have not yet enforced superior returns versus peers.

The absence of visible dilution pressure is constructive, but it does not demonstrate that management incentives are tightly tied to long-term value creation.

With limited disclosure on equity ownership and performance hurdles, incentive quality appears average rather than clearly stronger than peer norms.

Overall Score

Score:

Management quality appears mixed, with conservative balance-sheet decisions offset by weak profitability and limited evidence of superior value creation versus peers.

Score Driver: Negative ROE Despite Moderate Leverage

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Calidi Biotherapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →